Gild stock forecast analysts maintain a cautiously bullish

Analysts maintain a cautiously bullish GILD stock forecast as biotech sector momentum improves. The firm’s strong cash position of $8B supports ongoing R&D, which could catalyze near-term breakouts if trial data beats expectations. Morgan Stanley Maintains Buy on Gilead Sciences ( GILD ) Its strong cash position (as of Dec. 31, 2024, GILD had $10 billion of cash, cash equivalents and marketable debt securities) indicates that the current yield of 2.84% is sustainable. Market models in recent GILD stock forecast analyses highlight a potential breakout if quarterly sales exceed $7B. Moving averages show steady bullish crossover patterns.